Related Experiment Video
Updated: Oct 27, 2025
04:56
Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
Published on: August 4, 2023
934
COVID-19-related laboratory coagulation findings
1Coagulation Laboratory, Department of Laboratory Medicine, Department of Diagnostic Sciences, Ghent University Hospital, Ghent University, Ghent, Belgium.
International Journal of Laboratory Hematology
|July 21, 2021
Summary
COVID-19 significantly disrupts hemostasis, increasing thrombosis risk. Elevated D-dimer is key for assessing thrombosis risk in patients, aiding diagnosis and management.
Area of Science:
- Hematology
- Infectious Diseases
- Critical Care Medicine
Background:
- COVID-19 is associated with significant hemostatic system disturbances.
- A high incidence of venous thromboembolism (VTE) is observed in COVID-19 patients, linked to altered coagulation parameters.
- Understanding these hemostatic changes is crucial for managing COVID-19 complications.
Purpose of the Study:
- To review the role of hemostasis testing in diagnosing and managing COVID-19 patients.
- To highlight key laboratory markers for thrombosis risk assessment in COVID-19.
- To discuss the utility of various coagulation parameters in the context of COVID-19.
Main Methods:
- Review of current literature on hemostasis and COVID-19.
- Analysis of diagnostic laboratory parameters relevant to coagulation.
- Evaluation of markers for thrombosis risk assessment and monitoring.
Main Results:
- Elevated D-dimer levels are a critical marker for thrombosis risk in COVID-19.
- Prothrombin time and platelet count are important in the diagnostic approach.
- Fibrinogen may indicate worsening coagulopathy; other markers have limited diagnostic/management roles currently.
- Anti-Xa assay is recommended for monitoring heparin therapy due to aPTT alterations.
Conclusions:
- Hemostasis testing plays a vital role in COVID-19 patient management.
- D-dimer is a crucial marker for thrombosis risk stratification.
- While some markers aid pathophysiological understanding, their clinical utility in diagnosis and management is limited, except for anti-Xa in heparin monitoring.
Keywords:
COVID-19anticoagulationcoagulation assayscoagulopathycoronavirushemostasislaboratory teststhromboembolismMore Related Videos
Related Concept Videos
01:06Coagulation
494
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
494
01:09Coagulation
8.5K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
8.5K
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
80
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
80
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.1K
01:24Disorders of Hemostasis
1.4K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.4K
02:45Blood Transfusion and Agglutination
12.0K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
12.0K